ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406
Martin J. van den Bent(Erasmus MC Cancer Institute), Vassilis Golfinopoulos(Champalimaud Foundation), Hao Xiong(Shanghai Jiao Tong University), Michael Weller(University Hospital of Zurich), Joana Brilhante(Advantest (Singapore)), Pim J. French(Erasmus MC Cancer Institute), Iris de Heer(Erasmus MC Cancer Institute), Jim Looman(AbbVie (United States)), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Peter Ansell(AbbVie (United States)), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean-Sebastian Frenel, Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Jyotirmoy Dey(AbbVie (United States)), Scott Krause, Paul M. Clément(Universitair Ziekenhuis Leuven), Maarten Spruyt(European Organisation for Research and Treatment of Cancer), Annemiek Walenkamp(University Medical Center Groningen)
Cited by 4
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k